drugset / Trial / NCT02706899
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).
Timeline
- Start
- 2016-02
- Primary completion
- 2017-11-06
- Completion
- 2017-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vadastuximab talirine | Unknown | — | Intravenous |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |